Leerink Partnrs Analysts Increase Earnings Estimates for bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. (NASDAQ:BLUE) – Equities research analysts at Leerink Partnrs raised their Q2 2024 earnings per share (EPS) estimates for bluebird bio in a report issued on Tuesday, September 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will earn ($0.33) per share for the quarter, up from their previous forecast of ($0.35). The consensus estimate for bluebird bio’s current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for bluebird bio’s Q3 2024 earnings at ($0.39) EPS, Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.22) EPS.

A number of other equities research analysts have also issued reports on BLUE. JPMorgan Chase & Co. lowered bluebird bio from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 15th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of bluebird bio in a report on Thursday, August 15th. StockNews.com initiated coverage on bluebird bio in a research note on Friday. They set a “sell” rating for the company. Robert W. Baird cut their price target on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Finally, Barclays lowered their price objective on bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 15th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.63.

bluebird bio Price Performance

bluebird bio stock opened at $0.50 on Friday. The company has a quick ratio of 0.82, a current ratio of 0.93 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $55.15 million, a P/E ratio of -0.68 and a beta of 0.75. The firm has a fifty day moving average of $0.77 and a 200-day moving average of $0.97. bluebird bio has a 52-week low of $0.46 and a 52-week high of $5.53.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BLUE. Masters Capital Management LLC bought a new stake in bluebird bio in the fourth quarter worth about $1,380,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of bluebird bio by 38.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 90,139 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of bluebird bio in the 4th quarter worth $317,000. HBK Investments L P acquired a new stake in shares of bluebird bio during the fourth quarter worth $2,070,000. Finally, Vestal Point Capital LP purchased a new stake in shares of bluebird bio during the fourth quarter valued at $2,967,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.